Uplizna Injection
Product Images NDC 75987-150

3 FDA label images from Horizon Therapeutics Usa, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Uplizna (NDC 75987-150). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Horizon Therapeutics Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 Kaplan-meier Plot Of Time To First Adjudication Committee-determined Nmosd Relapse In The Randomized-controlled Period (itt Population; Anti-aqp4 Antibody Positive Patients) (Inebilizumab Injection 100 mg Per 10 mL 01)

Figure 1 Kaplan-meier Plot Of Time To First Adjudication Committee-determined Nmosd Relapse In The Randomized-controlled Period (itt Population; Anti-aqp4 Antibody Positive Patients) (Inebilizumab Injection 100 mg Per 10 mL 01)
A Kaplan-Meier curve showing relapse-free probability over time (days) comparing UPLIZNA (inebilizumab) and placebo groups. The graph indicates higher relapse-free probability with UPLIZNA versus placebo. Below the graph is a table showing the number of patients at risk for each group at various time points.*
FDA Label Image

Principal Display Panel (100 mg/10 mL Vial Carton)

Principal Display Panel (100 mg/10 mL Vial Carton)
UPLIZNA 10 mg/mL injection label showing packaging for intravenous use. The label states the product contains 3 single-dose vials with 100 mg per 10 mL (10 mg/mL) of inebilizumab-cdon. It includes storage instructions at 2°C to 8°C, dilution requirements, manufacturer Horizon Therapeutics Ireland, and distributor Horizon Therapeutics USA, Inc. The NDC 75987-150-03 and barcode are visible with pharmacist dispensing instructions and Horizon logo.*
FDA Label Image

Principal Display Panel (100 mg/10 mL Vial Label)

Principal Display Panel (100 mg/10 mL Vial Label)
Label for UPLIZNA injection, 10 mg/mL (100 mg/10 mL) single-dose vial containing inebilizumab-cdon. The label indicates the product is for intravenous infusion after dilution, includes storage instructions, preparation details, and a barcode. Manufactured by Horizon Therapeutics USA, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.